Çocuklarda İmmünomodülatör Tedavi ve IVIG Uygulamaları
Özet
Nöroimmünolojik hastalıklar, sinir sistemi ile bağışıklık sistemi arasındaki etkileşimin bozulmasıyla ortaya çıkar ve çocukluk çağında MS, Guillain-Barré sendromu, myastenia gravis ve otoimmün ensefalit gibi ciddi tablolara yol açar. Tedavide temel amaç immün yanıtı düzenlemektir; bu kapsamda intravenöz immünglobulinler (IVIG), kortikosteroidler ve azatiopürin gibi immünsüpresif ajanlar ile rituksimab ve ekulizumab gibi monoklonal antikorlar yaygın olarak kullanılır. Uygulanan bu tedaviler, inflamasyonu baskılayarak hastalığın ilerlemesini durdurmayı, atakları azaltmayı ve nörolojik hasarı minimize etmeyi hedefler. Her bir yaklaşımın klinik yanıtı, yan etki profili ve uygulama şekli hastanın yaşına, hastalığın türüne ve şiddetine göre dikkatle planlanmalıdır.
Neuroimmunological diseases arise from the dysregulation of interactions between the nervous system and the immune system, leading to serious conditions in childhood such as MS, Guillain-Barré syndrome, myasthenia gravis, and autoimmune encephalitis. The primary goal of treatment is to modulate the immune response; therefore, therapeutic strategies commonly include intravenous immunoglobulins (IVIG), immunosuppressive agents like corticosteroids and azathioprine, and monoclonal antibodies such as rituximab and eculizumab. These treatments aim to suppress inflammation, halt disease progression, reduce relapses, and minimize neurological damage. Clinical response, side effect profiles, and administration methods for each approach must be carefully planned based on the patient's age, as well as the type and severity of the disease.
Referanslar
Villoslada P, Moreno B, Melero I, et al. Immunutheraphy for Neurological diseases. Clin Immunol 2008;128:294-305
Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. New Eng J Med 2012;367:2015-2025
Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.Proc Natl Acad Sci U S A. 2009 ;106(12):4788-92
Dalakas MC, Dambrosia JM, Soueidan SA, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. Engl J Med. 1993;329(27):1993-2000
Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl. 2005;11(12):1469-1480
Menon D, Sarpong E, Bril V. Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders. Can J Neurol Sci. 2021 Mar 26:1-7.
Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012 Dec 12;12(12):2277.
Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43(10):1460-80.
Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337-42.
Wajanaponsan N, Cheng SF. Acute renal failure resulting from intravenous immunoglobulin therapy. Hawaii Med J. 2004;63(9):266-7.
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-1228.
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014:CD002063.
Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):8-14.
Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021;20(1):102712.
M.C. Dalakas. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-1497
O. Hilkevich, V.E. Drory, J. Chapman, A.D. Korczyn. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharm 2001;24:173-176
Beecher G, Anderson D, Siddiqi ZA. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial. Neurology. 2017;89(11):1135-1141.
Konuskan B, Anlar B. Treatment in childhood central nervous system demyelinating disorders. Dev Med Child Neurol. 2019 Nov;61(11):1281-1288.
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with antiNMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–65.
Balu R, McCracken L, Lancaster E, et al. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 2019;92:244–52
Uy CE, Binks S, Irani SR. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol. 2021;2020-002567.
Billiau An D, Witters P, Ceulemans B, et al. Intravevous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity and cerebrospinal fluid cytokine profile. Epilepsia 2007; 48: 1739–1749.
Lagae LG, Silberstein J, Gillis PL, Caesaer PJ. Successful use of intravenous immunoglobulins in Landau-Kleffner syndrome. Pediatric Neurology 1998;18:165–168.
Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol. 2001;117(1-2):1-8.
S. Ramanathan, S. Mohammad, E. Tantsis, et al., Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, J. Neurol. Neurosurg. Psychiatry 2018:89;127-137.
L. Pandit, S. Mustafa, I. Nakashima, T. Takahashi, K. Kaneko, MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response, Mult Scler J Exp Transl Clin 2018:4; 2055217318787829
Stingl C, Cardinale K, Van Mater H. An Update on the Treatment of Pediatric Autoimmune Encephalitis. Curr Treatm Opt Rheumatol. 2018 Mar;4(1):14-28.
Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2020:25;1:CD008630.
Hughes RA, Donofrio P, Bril V, et al. ICE Study Group Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008:7;136–144
Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78:1974–80.
Eliyan Y, Heesch J, Alayari A, Rajaraman RR, Sankar R, Hussain SA. Very-high-dose prednisolone before ACTH for treatment of infantile spasms: evaluation of a standardized protocol. Pediatr Neurol. 2019;99:16–22.
Wanigasinghe J, Arambepola C, Sri Ranganathan S, Sumanasena S, Attanapola G. Randomized, single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular corticotropin on immediate and continued spasm control in West syndrome. Pediatr Neurol. 2015;53:193–9
Bruijstens AL, Wendel EM, Lechner C et al. E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41-53.
W. Qiu, A.G. Kermode, R. Li, Y. Dai, Y. Wang, J. Wang, et al., Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica, J. Clin. Neurosci. 2015;22:1178-1182.
Z. Nikoo, S. Badihian, V. Shaygannejad, N. Asgari, F. Ashtari, Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial, J. Neurol. 2017;264:2003-2009.
Y. Hacohen, Y.Y. Wong, C. Lechner, M. et al.,Disease course and treatment responses in children with relapsing myelinoligodendrocyte glycoprotein antibody- associated disease, JAMA Neurol 2019;75:478-487.
A. Cobo-Calvo, M. Sepulveda, F. Rollot, T, et al., Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease, J. Neuroinflammation 2019; 16:134.
J.J. Lipsky, Mycophenolate mofetil, Lancet 1996;348:1357-1359.
Y. Xu, Q. Wang, H.T. Ren, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study, J. Neurol. Sci.2016; 370: 224-228.
Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):705
S. Vernino, D.R. Salomao, T.M. Habermann, B.P. O’Neill Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil Neurology, 2005;65:639-641
D.B. Dubal, S. Mueller, B.S. Ruben, J.W. Engstrom, S.A. Josephson T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis Muscle Nerve, 2009;39:849-850
L.D. Hobson-Webb, M. Hehir, B. Crum, A. Visser, D. Sanders, T.M. Burns Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis Muscle Nerve, 2015;52:211-215
Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol Nature Publishing Group. 2009; 6:638–47
Stingl C, Cardinale K, Van Mater H. An Update on the Treatment of Pediatric Autoimmune Encephalitis. Curr Treatm Opt Rheumatol. 2018;4(1):14-28.
Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel). 2021;14(2):92.
Whittam DH, Tallantyre EC, Jolles S, et al. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology, 2019;19:5-20.
Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3:188.
Nepal G, Shing YK, Yadav JK, et al. Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis. Acta Neurologica Scandinavica, 2020;142:449-59
Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 2018;75:320–27.
Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology, 2021;96:114-22.
Dale RC, Brilot F, Duffy LV,et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014;83:142-50.
Highlights of prescribing information. Available at: http:// www.gene.com/download/pdf/rituxan_prescribing.pdf. Accessed February 1, 2014.
Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256–1264.
Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 2019;60(1):14–24.
Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(7):614-625.
Kürtüncü, M. Multipl Sklerozda Natalizumab Tedavisi. Archives of Neuropsychiatry/Noropsikiatri Arsivi 2011:48.
Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014 Dec;76(6):802-12.
von Glehn F, Farias AS, de Oliveira AC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012 Jul;18(7):1038-41.
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016:19;4
McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet. 2021 Jun 24:S0140-6736(21)00244-0.
Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler. 2002 Dec;8(6):485-91.
McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021 Feb 23;325(8):765-779.
Galldiks N, Dohmen C, Neveling M, Fink GR, Haupt WF. Selectiveimmune adsorption treatment of severe GuillaineBarre ́-syndrome inthe intensive care unit. Neurocrit Care 2009;11:317-21.
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews. 2014(9):CD002063
Nagayasu T, Yamayoshi T, Matsumoto K, et al. Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis. Japanese J Thorac Cardiovasc Surg 2005;53:2-7
Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346-51.
Schwartz J, Padmanabhan A, Aqui N, et al.Guidelines on the use of therapeutic apheresis in clinical Practice—Evidence-Based approach from the writing Committee of the American Society for apheresis:the seventh special issue.J Clin Apher 2016;31(3):149-338.
Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. The Lancet. 2005;366(9485):579-82.
Klingel R, Heibges A, Fassbender C. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies perspectives for immunoadsorption. Atheroscler Suppl. 2013 Jan;14(1):161-5.
Latimer ME, L'Etoile N, Seidlitz J, Swedo SE. Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Child Adolesc Psychopharmacol. 2015;25:70-5.
Osman C, Jennings R, El-Ghariani K, Pinto A. Plasma exchange in neurological disease. Practical neurology. 2020;20:92-9.
